Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft® Sep 6, 2024
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 Jul 23, 2024
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4) Jul 1, 2024
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft® May 16, 2024
